Welcome to the e-CCO Library!

DOP030: The efficacy of home telemonitoring vs. conventional follow-up: a randomised controlled trial among teenagers with inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Heida1, A. Muller Kobold2, J. Rossen3, A. Kindermann4, F. Kokke5, T. Meij, De6, O. Norbruis7, R. Weersma8, M. Wessels9, T. Hummel10, H. Escher11, H. Wering, van12, D. Hendriks13, L. Mearin14, H. Groen15, H. Verkade1, P. Van Rheenen1*

Created: Thursday, 21 February 2019, 9:14 AM
DOP031: Efficacy of infliximab biosimilar CT-P13 therapy on mucosal healing in ulcerative colitis: data from 2 Central European countries
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

K. Farkas1, M. Rutka1, P.A. Golovics2, Z. Végh2, B.D. Lovász2, T. Nyári3, K.B. Gecse2, M. Kolar4, 5, M. Bortlik4, 6, D. Duricova4, 7, N. Machkova4, V. Hruba4, M. Lukas4, K. Mitrova4, 8, K. Malickova9, A. Bálint1, F. Nagy1, R. Bor*1, A. Milassin1, Z. Szepes1, K. Palatka10, P.L. Lakatos2, M. Lukas4, 9, T. Molnár1

Created: Friday, 22 February 2019, 9:49 AM
DOP031: Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice
Year: 2018
Source: ECCO '18 Vienna
Authors:

D.V. Ankersen*, D. Marker, P. Weimers, J. Burisch, P. Munkholm

Created: Thursday, 21 February 2019, 9:14 AM
DOP031: Subtherapeutic serum infliximab trough levels and complete mucosal healing are associated with sustained clinical remission after infliximab discontinuation in paediatric Crohn's disease patients
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kang B.*1, Lee K.1, Kim K.2, Lee J.H.3, Choe Y.H.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP032: Crohn’s disease patients’ perspectives towards de-escalating immunosuppressive therapy: a comparative French and American survey
Year: 2018
Source: ECCO '18 Vienna
Authors:

C.A. Siegel1*, K.D. Thompson2, D. Walls3, J. Gollins4, A. Buisson5, A. Olympie5, L. Beaugerie6, J.-F. Colombel7, E. Louis on behalf of the BIOCYCLE group8

Created: Thursday, 21 February 2019, 9:14 AM
DOP032: Hydrocortisone premedication withdrawal in patients on stable infliximab maintenance: clinical and pharmacokinetic outcomes
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Tran-Minh M.-L.*1, Maillet M.1, Auzolle C.1,2, Simon M.3, Cathala A.L.1, Aparicio T.1,2, Baudry C.1, Bonnet J.1, Lourenco N.1, Houze P.4, Gornet J.-M.1, Allez M.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
DOP032: Switching of patients with inflammatory bowel disease from original infliximab (Remicade®) to biosimilar infliximab (Remsima™) is effective and safe
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Kolar*1, D. Duricová2, M. Brotlik1, V. Hruba1, N. Machkova1, K. Mitrova1, K. Malickova3, M. Lukas1, M. Lukas1

Created: Friday, 22 February 2019, 9:49 AM
DOP033: Immunogenicity profile and predictors of TLs and ADA development of biosimilar infliximab during the first 6 months of the therapy: results from a prospective nationwide cohort
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

B. Lovasz*1, Z. Kurti1, M. Rutka2, Z. Vegh1, K. Gecse1, K. Farkas2, J. Banai3, L. Bene4, B. Gasztonyi5, T. Kristof6, L. Lakatos7, P. Miheller8, K. Palatka9, A. Patai10, A. Salamon11, T. Szamosi3, Z. Szepes12, E. Biro13, G.T. Toth14, A. Vincze15, T. Molnar2, P. Lakatos1

Created: Friday, 22 February 2019, 9:49 AM
DOP033: Severely active ulcerative colitis is associated with high baseline infliximab clearance, reduced serum half-life and worse endoscopic outcomes
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Vande Casteele N.*1,2, Jairath V.3,4, Levesque B.1,2, Feagan B.3,4, Sandborn W.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
DOP033: Trends in epidemiology of inflammatory bowel disease among Jewish Israeli adolescents: a population-based study
Year: 2018
Source: ECCO '18 Vienna
Authors:

I. Ghersin1*, L.H. Katz2, S. Daher3, R. Shamir4, A. Assa4

Created: Thursday, 21 February 2019, 9:14 AM
DOP034: Assessment of direct healthcare cost drivers of Crohn’s disease in a Dutch population-based cohort study shows a major shift
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Lalisang1*, D. Wintjens1,2, M. Romberg-Camps3, A. van Bodegraven3, L. Oostenbrug3, J. Haans1, A. Masclee1,2, D. Jonkers1,2, M. Pierik1,2

Created: Thursday, 21 February 2019, 9:14 AM
DOP034: Comparative effectiveness of infliximab and adalimumab in Crohns disease: results from a real-life population-based cohort
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Jeuring*1, 2, D. Wintjens1, T. Van den Heuvel1, 2, M. Zeegers3, 4, 
W. Hameeteman1, M. Romberg-Camps5, L. Oostenbrug6, A. Masclee1, 2, D. Jonkers1, 2, M. Pierik1, 2

Created: Friday, 22 February 2019, 9:49 AM
DOP034: Serum adalimumab concentration 3 months after surgery is correlated with endoscopic recurrence in Crohn's disease patients treated with adalimumab for prevention of postoperative recurrence
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Boivineau L.*1, Bourgaux J.F.2, Pineton de Chambrun G.1, Caillo L.2, Danan G.1, Boitard J.1, Liautard J.1, Guillon F.1, Altwegg R.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP035: Beclomethasone dipropionaat is effective for microscopic colitis: results of an open-label multicentre study (COLCO)
Year: 2018
Source: ECCO '18 Vienna
Authors:

T. De Corte1, E. Janssens1*, K. Thorrez2, A. D'Hondt1, K. Dejaegher3, F. D'Heygere4, B. van Besien2, L. Harlet1, H. Peeters5, W. Vanmoerkercke4, P. van Hootegem6, F. Baert1

Created: Thursday, 21 February 2019, 9:14 AM
DOP035: High gammaglobulin and low albumin serum levels independently predict secondary loss of response to anti-TNFα therapy in IBD
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Schoenefuss F., Hoffmann P.

Created: Wednesday, 20 February 2019, 10:36 AM
DOP035: Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα –blocking agents
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

P. Molander*1, 2, M. Färkkilä2, 3, H. Kemppainen4, T. Blomster5, A. Jussila6, H. Mustonen7, T. Sipponen2, 3

Created: Friday, 22 February 2019, 9:49 AM
DOP036: Infliximab discontinuation is associated with a higher risk for relapse in patients with ulcerative colitis in remission: a multinational collaborative retrospective study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. Fiorino*1, P. Ellul2, M. Muscat2, P. Karatzas3, M. Silva4, A. Peixoto4, C. Felice5, F. Bossa6, P.L. Lakatos7, S. Sebastian8, B. Ungar9, F. Furfaro1, K. Karmiris10, K.H. Katsanos11, P. Navarro Cortes12, M.M. Boscà Watts12, D.K. Christodoulou11, G. Maconi13, U. Kopylov9, A. Armuzzi5, F. Magro4, G. Mantzaris3, S. Ben-Horin9, S. Danese1, 14

Created: Friday, 22 February 2019, 9:49 AM
DOP036: The therapeutic efficacy of anti-TNF requires Fc-gamma receptors and can be improved by antibody hypo-fucosylation
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bloemendaal F.*1, Levin A.2, Wildenberg M.2, Koelink P.2, Visser R.3, Claassens J.4, Bradford M.5, D'Haens G.2, Verbeek S.4, Vidarsson G.3, van den Brink G.2

Created: Wednesday, 20 February 2019, 10:36 AM
DOP036: Ustekinumab for Crohn’s disease: a nationwide real-life observational cohort study (ICC case series)
Year: 2018
Source: ECCO '18 Vienna
Authors:

V. Biemans1,2*, A. van der Meulen - de Jong3, C. van der Woude4, N. de Boer5, G. Dijkstra6, B. Oldenburg7, C. Ponsioen8, P. Maljaars3, J. Haans2, M. Pierik2, F. Hoentjen9, Dutch Initiative on Crohn and Colitis (ICC)

Created: Thursday, 21 February 2019, 9:14 AM
DOP037: A model for prediction of early surgery and complications in paediatric Crohn's disease: results of the prospective GROWTH CD study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Levine A.*1,2, Hussey S.3, Kolho K.L.4, Sladek M.5, de Carpi J.M.6, Turner D.7, Russell R.K.8, Cohen-Dolev N.9, Escher J.10 Porto-ECCO GROWTH CD Study Group

Created: Wednesday, 20 February 2019, 10:36 AM